AMETEK Acquires FARO Technologies in $920 Million Deal to Expand Precision Measurement Capabilities

Key Points:
– AMETEK will acquire FARO Technologies for $920M, paying $44/share in cash—a 40% premium.
– FARO brings $340M in annual sales and advanced 3D metrology tools to AMETEK’s precision portfolio.
– The deal is expected to close in H2 2025, strengthening AMETEK’s presence in industrial and tech-driven sectors.

AMETEK, a global leader in electronic instruments and electromechanical devices, has announced it will acquire FARO Technologies in an all-cash deal valued at approximately $920 million. The acquisition is set to enhance AMETEK’s portfolio in precision measurement and 3D imaging, reinforcing its strategy of expanding into high-growth technology segments.

Under the terms of the agreement, AMETEK will pay $44 per share in cash for FARO, representing a roughly 40% premium to FARO’s previous closing price. The deal implies an equity value of $846 million and an enterprise value of $920 million. The acquisition is expected to close in the second half of 2025, pending customary closing conditions and regulatory approvals.

FARO Technologies, headquartered in Lake Mary, Florida, is a prominent provider of 3D measurement, imaging, and realization technology. Its suite of products includes portable measurement arms, laser scanners, and laser trackers used widely across manufacturing, engineering, construction, and public safety applications. The company reported approximately $340 million in sales for 2024, making it a valuable addition to AMETEK’s electronic instruments segment.

“This acquisition aligns well with our strategy of investing in differentiated technology businesses with strong market positions and attractive growth characteristics,” said David Zapico, Chairman and CEO of AMETEK. “FARO’s innovative 3D measurement and imaging solutions will strengthen our presence in precision metrology and expand our reach into new markets and applications.”

FARO’s technologies are used in sectors ranging from aerospace and automotive to architecture and law enforcement—markets that AMETEK sees as key growth areas. The deal reflects AMETEK’s broader aim to build out its capabilities in high-precision, high-performance technologies that deliver value across complex industrial environments.

While FARO shares jumped 36% in pre-market trading following the announcement, AMETEK shares remained flat, reflecting a neutral reaction from investors. However, analysts noted that the acquisition could offer long-term synergies, particularly as AMETEK integrates FARO’s product line and customer relationships into its existing operations.

AMETEK has a track record of strategic, bolt-on acquisitions that complement its core businesses. The company recently reported better-than-expected earnings for Q1 2025, driven by improved margins and resilient demand despite ongoing inflationary pressures and global trade uncertainties. CEO David Zapico noted that AMETEK’s strong U.S. manufacturing footprint positions it well to benefit from shifting supply chain dynamics and tariff-related opportunities.

“The current trade environment is creating strategic openings for manufacturers like AMETEK,” Zapico said last week. “This acquisition allows us to serve a broader range of customers looking for advanced measurement technologies built in America.”

FARO will operate under AMETEK’s Electronic Instruments Group, a division known for producing advanced monitoring, testing, and analytical equipment for industries that demand high accuracy and reliability.

The acquisition further solidifies AMETEK’s position as a leader in precision instrumentation, while giving FARO the resources and scale to accelerate innovation and expand its market reach. With both companies emphasizing long-term value and technical excellence, the deal appears well-aligned for success.

Titan Medical Announces Transformative Merger with Conavi Medical

Toronto-based medical device company Titan Medical Inc. (TSX: TMD) unveiled a definitive agreement to merge with Conavi Medical Inc. in an all-stock transaction that will create a new publicly-traded leader in hybrid intravascular imaging.

The deal, announced on March 18, 2024, will see Titan acquire all of the outstanding shares of Conavi, a commercial-stage firm that has developed the Novasight Hybrid System for guiding minimally invasive coronary procedures. In exchange, Conavi shareholders will receive newly issued shares of Titan.

The merger will constitute a reverse takeover of Titan by Conavi. Upon completion, the combined entity plans to change its name to Conavi Medical Inc. and apply to list its shares on the TSX Venture Exchange after delisting from the Toronto Stock Exchange.

“This planned merger comes at a pivotal moment as we advance the Novasight Hybrid System, unlocking its full potential in the U.S. and globally,” said Thomas Looby, CEO of Conavi. “Gaining public company status will enhance our financial strength and growth strategy.”

Conavi’s Novasight Hybrid system is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging modalities, enabling simultaneous and co-registered imaging of coronary arteries. It has regulatory approvals in the U.S., Canada, China and Japan.

Paul Cataford, Interim CEO and Board Chair of Titan, said “Conavi is an exciting commercial-stage company with groundbreaking technology. We are confident in their ability to drive adoption of the Novasight Hybrid System.”

As part of the transaction, Conavi will complete a concurrent equity financing raising between $15-20 million before the deal closes around July 15th. The financing is expected to attract support from institutional investors.

Take a moment to take a look at Noble Capital Markets’ Senior Research Analyst Robert Leboyer’s coverage universe.

Key benefits anticipated for the combined company include a strong balance sheet following the financing, established product capabilities, a proven coronary imaging product being commercialized, a large market opportunity, and increasing user traction.

Under the agreement terms, Titan will consolidate its shares on an agreed ratio prior to the merger. A Titan subsidiary will then amalgamate with Conavi, with Titan issuing new consolidated shares to Conavi shareholders based on an exchange ratio valuing Conavi at $69.84 million pre-money. This ratio will ensure existing Titan shareholders own at least 10% of the combined company.

All officers and certain Titan directors will resign upon closing and be replaced by Conavi nominees. The merger requires approval from shareholders of both companies as well as regulatory approvals. Titan’s board unanimously recommends shareholders vote in favor based on a fairness opinion from its financial advisor.

The transaction marks the culmination of a strategic review process for Titan over the past 15 months. The company previously halted work on its surgical robotics program to conserve cash before pursuing asset sales and IP licensing deals.

With Conavi’s commercial hybrid imaging technology and anticipated financial resources from the merger and financing, the combined company aims to drive market penetration in the fast-growing field of intravascular imaging for coronary procedures. The deal transforms Titan from an R&D-stage firm into a revenue-generating medtech leader.